Lucid Diagnostics Inc. (LUCD)

0,8408 +0,0135 (+1,63%) Börsenschluss: 04:00PM EDT

Lucid Diagnostics Inc.

360 Madison Avenue
25th Floor
New York, NY 10017
United States
917 813 1828
https://www.luciddx.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 70

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Lishan Aklog M.D.	Chairman & CEO	300k	N/A	1966
Mr. Shaun M. O'Neill M.B.A.	President & COO	162,5k	N/A	1982
Mr. Dennis M. McGrath C.P.A.	Chief Financial Officer	225k	N/A	1957
Mr. Michael Adam Gordon	General Counsel & Secretary	250k	N/A	1975
Dr. Sanford D. Markowitz M.D., Ph.D.	Cofounder & Strategic Advisor, Member of the Medical Advisor Board	14,54k	N/A	N/A
Dr. Joseph Willis M.D.	Cofounder, Strategic Advisor & Member of Medical Advisory Board	N/A	N/A	N/A
Dr. Amitabh Chak M.D.	Cofounder, Strategic Advisor & Member of Medical Advisory Board	N/A	N/A	N/A
Richard D. Yazbeck	Chief Technology Officer	N/A	N/A	N/A
Dr. Suman M. Verma M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Dr. Brian J. deGuzman M.D.	Chief Compliance Officer	N/A	N/A	1965

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Corporate Governance

Lucid Diagnostics Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.